La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Regeneron Pharmaceuticals Gestione

Gestione criteri di controllo 4/4

Regeneron Pharmaceuticals' Il CEO è Leonard Schleifer, nominato in Jan1988, e ha un mandato di 36.58 anni. la retribuzione annua totale è $ 8.18M, composta da 22.9% di stipendio e 77.1% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 2.22% delle azioni della società, per un valore di $ 2.83B. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 7 anni e 17.7 anni.

Informazioni chiave

Leonard Schleifer

Amministratore delegato

US$8.2m

Compenso totale

Percentuale dello stipendio del CEO	22.9%
Mandato del CEO	36.6yrs
Proprietà del CEO	2.2%
Durata media del management	7yrs
Durata media del Consiglio di amministrazione	17.7yrs

Aggiornamenti recenti sulla gestione

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) CEO Compensation Looks Acceptable To Us And Here's Why

Jun 08

Recent updates

Risks To Shareholder Returns Are Elevated At These Prices For Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Aug 04

Regeneron's Robust Pipeline And Financial Health Signal Continued Growth

Aug 02

Regeneron: Downgrading My Outlook To 'Hold' Ahead Of Q2 Earnings

Jul 11

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) CEO Compensation Looks Acceptable To Us And Here's Why

Jun 08

These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

May 21

Regeneron: Dissecting The First Quarter Results And Regulatory Setbacks

May 06

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Popularity With Investors Is Under Threat From Overpricing

Apr 30

Is There An Opportunity With Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) 47% Undervaluation?

Apr 10

Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate

Mar 26

Regeneron Pharmaceuticals' (NASDAQ:REGN) Conservative Accounting Might Explain Soft Earnings

Feb 16

Regeneron Pharmaceuticals: Time To Change My Strategy After Encouraging Q4 2024

Feb 10

Regeneron's Push Into Obesity, Q4 2023 Earnings Review

Feb 02

These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

Jan 31

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Leonard Schleifer rispetto agli utili di Regeneron Pharmaceuticals?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	US$4b
Mar 31 2024	n/a	n/a	US$4b
Dec 31 2023	US$8m	US$2m	US$4b
Sep 30 2023	n/a	n/a	US$4b
Jun 30 2023	n/a	n/a	US$4b
Mar 31 2023	n/a	n/a	US$4b
Dec 31 2022	US$7m	US$2m	US$4b
Sep 30 2022	n/a	n/a	US$5b
Jun 30 2022	n/a	n/a	US$6b
Mar 31 2022	n/a	n/a	US$8b
Dec 31 2021	US$6m	US$2m	US$8b
Sep 30 2021	n/a	n/a	US$7b
Jun 30 2021	n/a	n/a	US$6b
Mar 31 2021	n/a	n/a	US$4b
Dec 31 2020	US$135m	US$1m	US$4b
Sep 30 2020	n/a	n/a	US$3b
Jun 30 2020	n/a	n/a	US$3b
Mar 31 2020	n/a	n/a	US$2b
Dec 31 2019	US$21m	US$1m	US$2b
Sep 30 2019	n/a	n/a	US$2b
Jun 30 2019	n/a	n/a	US$2b
Mar 31 2019	n/a	n/a	US$2b
Dec 31 2018	US$27m	US$1m	US$2b
Sep 30 2018	n/a	n/a	US$2b
Jun 30 2018	n/a	n/a	US$2b
Mar 31 2018	n/a	n/a	US$1b
Dec 31 2017	US$27m	US$1m	US$1b

Compensazione vs Mercato: La retribuzione totale di Leonard ($USD 8.18M ) è inferiore alla media delle aziende di dimensioni simili nel mercato US ($USD 13.21M ).

Compensazione vs guadagni: La retribuzione di Leonard è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Leonard Schleifer (71 yo)

36.6yrs

Mandato

US$8,184,338

Compensazione

Dr. Leonard S. Schleifer, M.D., Ph D., Co-founded Regeneron Pharmaceuticals, Inc. in 1988 and has been its President and Chief Executive Officer since 1988 and is its Board Co-Chair since June 2023. He ser...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Leonard Schleifer	Co-Founder	36.6yrs	US$8.18m	2.22% $ 2.9b
George Yancopoulos	Co-Founder	23.6yrs	US$7.76m	1.07% $ 1.4b
Andrew Murphy	Executive Vice President of Research	5.6yrs	US$8.43m	0.049% $ 63.0m
Daniel Van Plew	Executive VP and GM of Industrial Operations & Product Supply	16.3yrs	US$8.76m	0.031% $ 40.5m
Christopher Fenimore	Senior VP of Finance & CFO	less than a year	Nessun dato	0.023% $ 29.2m
Patrice Gilooly	Senior Vice President of Quality Assurance & Operations	4.6yrs	Nessun dato	Nessun dato
Bob McCowan	Senior VP of IT & Chief Information Officer	3.6yrs	Nessun dato	Nessun dato
Ryan Crowe	Senior Vice President of Investor Relations & Strategic Analysis	no data	Nessun dato	Nessun dato
Joseph LaRosa	Executive VP	12.9yrs	US$7.13m	0.035% $ 45.8m
Melissa Lozner	Senior VP & Chief Compliance Officer	1.6yrs	Nessun dato	Nessun dato
Christina Chan	Senior Vice President of Corporate Affairs	no data	Nessun dato	Nessun dato
Sally Paull	Executive Vice President of Human Resources	8.3yrs	Nessun dato	Nessun dato

7.0yrs

Durata media

64.5yo

Età media

Gestione esperta: Il team dirigenziale di REGN è esperto e expertise (durata media dell'incarico 7 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Leonard Schleifer	Co-Founder	36.6yrs	US$8.18m	2.22% $ 2.9b
George Yancopoulos	Co-Founder	23.6yrs	US$7.76m	1.07% $ 1.4b
Christine Poon	Lead Independent Director	13.8yrs	US$748.01k	0.00073% $ 943.0k
Arthur Ryan	Independent Director	21.6yrs	US$724.99k	0.016% $ 21.3m
Michael Brown	Independent Director	33.2yrs	US$728.99k	0.012% $ 15.0m
Joseph Goldstein	Independent Director	33.2yrs	US$709.99k	0.0046% $ 6.0m
George Sing	Independent Director	36.6yrs	US$724.99k	0.027% $ 35.4m
N. Coles	Independent Director	7.6yrs	US$704.99k	0.000010% $ 12.9k
Craig Thompson	Independent Director	1.8yrs	US$247.79k	0% $ 0
Huda Zoghbi	Independent Director	7.9yrs	US$714.99k	0% $ 0
Bonnie Bassler	Independent Director	7.9yrs	US$709.99k	0.0013% $ 1.7m
Kathryn Guarini	Independent Director	less than a year	US$1.03m	0% $ 0

17.7yrs

Durata media

71yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di REGN è composto da personale esperto e esperto (durata media dell'incarico 17.7 anni).

Regeneron Pharmaceuticals Gestione

Gestione criteri di controllo 4/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Executive Vice President of Research exercised options and sold US$15m worth of stock

Insider recently sold US$5.6m worth of stock

Executive VP exercised options and sold US$5.6m worth of stock

Co-Founder exercised options and sold US$1.0m worth of stock

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) CEO Compensation Looks Acceptable To Us And Here's Why

Co-Founder exercised options and sold US$104m worth of stock

Recent updates

Regeneron Provides Update on Biologics License Application for Linvoseltamab

Executive Vice President of Research exercised options and sold US$15m worth of stock

Insider recently sold US$5.6m worth of stock

Risks To Shareholder Returns Are Elevated At These Prices For Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Regeneron's Robust Pipeline And Financial Health Signal Continued Growth

Regeneron: Downgrading My Outlook To 'Hold' Ahead Of Q2 Earnings

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Approval in the European Union as the First-Ever Targeted Therapy for Patients with COPD

Regeneron Pharmaceuticals, Inc. Announces Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

Regeneron Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Regeneron Pharmaceuticals, Inc Announces Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine

Executive VP exercised options and sold US$5.6m worth of stock

Regeneron Pharmaceuticals, Inc. Announces 14-Month Median Follow-Up Data from the Pivotal Phase 1/2 Linker-MM1 Trial of Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma

Co-Founder exercised options and sold US$1.0m worth of stock

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) CEO Compensation Looks Acceptable To Us And Here's Why

Regeneron Pharmaceuticals, Inc and Sanofi Announces Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation

Regeneron Pharmaceuticals, Inc. Announces Positive New Results from an Ongoing Phase 1/2 Trial Evaluating its First-in-Class Costimulatory Bispecific Antibody, REGN7075 (EGFRxCD28)

Regeneron Pharmaceuticals, Inc. and Sanofi Presents Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in the New England Journal of Medicine

These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

Co-Founder exercised options and sold US$104m worth of stock

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application (sBLA) for Dupixent

Regeneron Pharmaceuticals, Inc. Announces Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness Within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks

Regeneron: Dissecting The First Quarter Results And Regulatory Setbacks

New minor risk - Shareholder dilution

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) announces an Equity Buyback for $3,000 million worth of its shares.

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Popularity With Investors Is Under Threat From Overpricing

Is There An Opportunity With Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) 47% Undervaluation?

Regeneron Pharmaceuticals, Inc. Announces Positive Pivotal Data from the Phase 1/2 LINKER-MM1 Trial of Linvoseltamab in Patients with Heavily Pre-Treated Multiple Myeloma

Regeneron Pharmaceuticals, Inc., Annual General Meeting, Jun 14, 2024

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) completed the acquiistion of R&D pipeline from 2seventy bio, Inc. (NasdaqGS:TSVT) for $20 million.

Regeneron Pharmaceuticals, Inc Provides Update on Biologics License Application for Odronextamab

Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate

Executive Vice President of Research exercised options and sold US$11m worth of stock

Regeneron Pharmaceuticals, Inc.'s Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol

Regeneron Pharmaceuticals, Inc. Announces the Lancet Published One-Year Results from the Pivotal Pulsar and Photon Trials for EYLEA HD (Aflibercept) Injection 8 Mg

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts Dupixent®? (Dupilumab) Sbla for Treatment of Copd with Type 2 Inflammation

Regeneron Pharmaceuticals, Inc. Announces Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review

Co-Founder exercised options and sold US$68m worth of stock

Regeneron Pharmaceuticals' (NASDAQ:REGN) Conservative Accounting Might Explain Soft Earnings

Regeneron Pharmaceuticals, Inc. and Sanofi Announces the Ministry of Health, Labor and Welfare in Japan Grants Marketing and Manufacturing Authorization for Dupixent (Dupilumab) for the Treatment of Chronic Spontaneous Urticaria

Insider exercised options and sold US$14m worth of stock

Regeneron Pharmaceuticals: Time To Change My Strategy After Encouraging Q4 2024

Insider recently sold US$7.6m worth of stock

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Regeneron Pharmaceuticals, Inc. Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma

Regeneron's Push Into Obesity, Q4 2023 Earnings Review

Regeneron Pharmaceuticals, Inc. Appoints Jason Pitofsky as Controller, Expects to Occur on February 5, 2024

These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

Regeneron Pharmaceuticals, Inc. and Sanofi Announce That U.S. Food and Drug Administration Approves Dupixent®? (Dupilumab) for the Treatment of Children Aged 1 Year and Older with Eosinophilic Esophagitis

Independent Director notifies of intention to sell stock

Regeneron Pharmaceuticals, Inc. and Sanofi Announce U.S. Food and Drug Administration Updates the Label for Dupixent (Dpilumab)

Regeneron Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 02, 2024

Senior VP notifies of intention to sell stock

Regeneron Pharmaceuticals, Inc. Announces New and Updated Data for Odronextamab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Pivotal Trial Showed Deep and the Potential of ctDNA to Predict Long-Term Outcomes

Regeneron Pharmaceuticals, Inc. Announces Updated Linvoseltamab Pivotal Data Demonstrated Strong Rates and Depth of Response in Patients with Heavily Pre-Treated Multiple Myeloma

Executive Vice President of Research exercised options and sold US$11m worth of stock

Regeneron Pharmaceuticals, Inc. Announces Presentation of New and Updated Data on Multiple Combination Therapies from its Oncology Pipeline at ESMO IO Congress 2023

Regeneron Pharmaceuticals, Inc. Announces the Second Dupixent (Dupilumab) Investigational Phase 3 Chronic Obstructive Pulmonary Disease (COPD) Trial

Regeneron Pharmaceuticals, Inc. Announces the Second Dupixent (Dupilumab) Investigational Phase 3 Chronic Obstructive Pulmonary Disease (COPD) Trial

Executive Vice President of Research exercised options and sold US$11m worth of stock

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Regeneron Pharmaceuticals, Inc. Announces Long-Term Outcomes and New Analyses of Pivotal Clinical Data for EYLEA®? HD (aflibercept) Injection 8mg

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media